Atlanta medical device company Elekta (STO:EKTA B) this week announced FDA clearance for its Versa HD linear accelerator, allowing the company to move forward with shipping and installations.

The next-generation Versa HD targets tumors with precision beam shaping and can delivery radiation 3 times faster than previous Elekta devices, and it consumed up to 30% less energy than its peers, according to a press release.

Elekta initially unveiled the Versa HD via a live launch event publicized last month. The newly cleared device can treat a wide range of tumors in the body with "extreme targeting precision," according to company documents.

The Versa HD integrates with Elekta’s Agility 160-leaf multileaf collimator to provide precision beam shaping, allowing doctors to target tumors with high doses of radiation while preserving nearby healthy tissue. The devices also allow radiation therapy to reach more targets at a faster speed.

"Historically, high-definition beam shaping often was mechanically limited to only small target therapies," according to a company report. "Versa HD with Agility overcomes this challenge, now empowering clinicians to deliver extremely precise beam contouring for both small and large targets."

EKTA-B shares were up 0.9% to SEK 99.40 as of the close of the Stockholm Stock Exchange.